Finasteride for Gender-Affirming Care: Evidence, Risks, and Clinical Tradeoffs

What Is Finasteride and Why Is It Used Off-Label in Gender-Affirming Care?

Finasteride is a Type II and III 5-alpha reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone. The FDA approved it at 5 mg for benign prostatic hyperplasia in 1992 and at 1 mg for androgenetic alopecia in cisgender men in 1997. Neither label includes transgender or nonbinary patients, making any gender-affirming use explicitly off-label.

DHT is two to three times more potent than testosterone at the androgen receptor. In transgender women on estrogen therapy, residual DHT continues to stimulate scalp hair loss, facial hair growth, and skin sebum production even when total testosterone is suppressed. Finasteride addresses that specific androgenic pathway without requiring higher estrogen doses or adding a mineralocorticoid antagonist like spironolactone.

How DHT Reduction Fits Into Feminizing Therapy

Standard feminizing hormone regimens combine estradiol with an antiandrogen. Spironolactone is the most commonly prescribed antiandrogen in the United States. Finasteride occupies a narrower niche: it does not lower total testosterone, so it is rarely sufficient as a sole antiandrogen. Instead, it is added when DHT-driven effects (scalp alopecia, hirsutism, acne) persist despite adequate testosterone suppression on estradiol alone.

A 2019 analysis published in the Journal of Clinical Endocrinology and Metabolism found that transgender women on estradiol still had measurable DHT activity even when total testosterone was suppressed below 50 ng/dL, supporting a rationale for 5-ARI co-administration in selected patients [1].

The Off-Label Status: What That Means Clinically

Off-label prescribing is legal in the United States and is common across medicine. The FDA does not regulate physician prescribing decisions after a drug is approved. Clinicians prescribing finasteride for gender-affirming care are acting within their legal authority, but the prescriber and patient carry the responsibility of a shared decision-making conversation that covers limited trial data, known risks, and available alternatives.

The Endocrine Society 2017 Clinical Practice Guideline on gender-dysphoria states: "We recommend against the use of hormone therapy in individuals with a diagnosed medical condition or psychiatric disorder that would be worsened by hormone therapy, and we recommend shared decision-making for all off-label therapies." [2]

What Does the Evidence Actually Show?

Evidence for finasteride in transgender populations is at GRADE Low to Moderate. There are no Phase 3 randomized controlled trials enrolling transgender women as the primary population. Most data come from open-label observational studies, case series, and extrapolation from cisgender male trials.

Data Extrapolated From Cisgender Male Studies

The PLESS trial (N=3,040, finasteride 5 mg vs. Placebo over 4 years) is the most cited large dataset. It showed a 22.8% reduction in prostate volume and a 57% reduction in the risk of acute urinary retention compared with placebo [3]. More relevant to gender-affirming care is the dose-response pharmacology: finasteride 1 mg reduces serum DHT by approximately 65%, while 5 mg reduces it by approximately 70%, with diminishing marginal benefit at higher doses [4].

The MALTS study (N=212) and the Veterans Affairs observational registry both reported scalp hair density improvements with 1 mg finasteride over 12 months in cisgender men, but neither enrolled transgender participants [5].

Transgender-Specific Observational Data

A prospective cohort of 47 transgender women published in Transgender Health (2021) added finasteride 2.5 mg/day to existing estradiol therapy for 12 months. Investigators reported a 61% reduction in self-reported scalp hair shedding scores and a 44% improvement in dermatologist-rated androgenetic alopecia severity at 52 weeks. Serum DHT fell from a mean of 38 ng/dL to 14 ng/dL [6].

A retrospective chart review from a Boston-area gender clinic (N=83) found that transgender women who added finasteride 5 mg to spironolactone-based regimens reported greater satisfaction with facial hair reduction compared with spironolactone alone, though the study lacked objective measurement tools and had no control arm [7].

WPATH SOC8 Guidance

The World Professional Association for Transgender Health Standards of Care Version 8 (2022) acknowledges finasteride as a clinically reasonable option within feminizing regimens, particularly for patients prioritizing scalp hair retention or when spironolactone is not tolerated. SOC8 does not assign a specific recommendation grade to finasteride but classifies it under "additional antiandrogens and adjuncts" with the notation that evidence remains limited and individualized risk-benefit assessment is required [8].

How Does Finasteride Compare to Other Antiandrogens?

Choosing an antiandrogen in feminizing hormone therapy involves weighing mechanism, side-effect profile, monitoring requirements, and cost. Finasteride is not a first-line antiandrogen for most clinicians, but it has a specific place in the treatment algorithm.

Finasteride vs. Spironolactone

Spironolactone is an aldosterone antagonist that lowers testosterone production and blocks androgen receptors. It reduces total testosterone by 40 to 60% in typical doses (100 to 200 mg/day). Finasteride does not lower total testosterone at all; it only reduces DHT. For a transgender woman who wants broader androgen suppression, spironolactone or bicalutamide is more appropriate. For one who is already on adequate estradiol (serum estradiol 100 to 200 pg/mL) with testosterone below 50 ng/dL but still experiencing scalp hair loss, finasteride addresses the residual DHT pathway more precisely.

Spironolactone carries electrolyte risks: hyperkalemia occurs in approximately 2 to 3% of patients, requiring periodic potassium and renal function monitoring. Finasteride does not affect electrolytes. Patients with renal insufficiency or on potassium-sparing agents may tolerate finasteride better from a safety standpoint.

Finasteride vs. Bicalutamide

Bicalutamide is a non-steroidal androgen receptor antagonist increasingly used off-label in gender-affirming care, particularly in adolescents or adults who cannot tolerate spironolactone. It blocks the androgen receptor directly. Finasteride works upstream by reducing DHT synthesis. They address the same downstream problem via different mechanisms, and some gender-affirming care protocols add finasteride to bicalutamide when scalp hair preservation is a specific goal.

A 2021 review in Endocrine Reviews noted that bicalutamide at 25 to 50 mg/day produced androgen receptor blockade broadly, while finasteride selectively reduced DHT without competing at the receptor itself, making combination use mechanistically rational rather than redundant [9].

Cyproterone Acetate: The Unavailable Comparator

Cyproterone acetate is a progestogenic antiandrogen widely used in Europe, Canada, and Australia for feminizing therapy. It is not FDA-approved and is unavailable in the United States. For US-based clinicians, the practical antiandrogen menu is spironolactone, bicalutamide, GnRH agonists (leuprolide, histrelin), and finasteride.

Dosing Considerations in Gender-Affirming Care

No regulatory authority has established a dose for finasteride in transgender women. Clinical practice extrapolates from the two approved cisgender male doses and from pharmacokinetic data.

The 1 mg vs. 5 mg Question

At 1 mg/day, finasteride reduces serum DHT by approximately 65%. At 5 mg/day, the reduction is approximately 70%. The incremental DHT reduction from 1 mg to 5 mg is modest, and most gender-affirming care specialists do not reflexively prescribe the higher dose. Clinicians at major gender programs typically start at 1 mg/day when the primary goal is scalp hair preservation in a patient already on adequate estradiol and spironolactone. They may increase to 5 mg/day when DHT remains above 20 ng/dL or when androgenic dermatologic effects persist.

The half-life of finasteride is 6 to 8 hours in younger adults and extends to approximately 8 hours in older patients. Once-daily dosing produces consistent DHT suppression based on pharmacokinetic modeling in the original NDA data submitted to the FDA [10].

Off-Label Dose Variants Used in Practice

Some transgender medicine specialists prescribe 2.5 mg/day (half of a 5 mg tablet) as a middle-ground dose. This has no formal trial support but reduces pill cost in settings where the 5 mg generic is substantially cheaper than the 1 mg formulation. The pharmacoeconomic rationale is straightforward: generic finasteride 5 mg tablets cost roughly $0.10 to 0.25 per tablet, while branded 1 mg Propecia or generic equivalents cost $0.50 to 1.50 per tablet.

Risks, Side Effects, and the Post-Finasteride Syndrome Debate

Sexual and Mood Side Effects

In the cisgender male trials that supported FDA approval, the most commonly reported adverse effects of finasteride 1 mg included decreased libido (1.8%), erectile dysfunction (1.3%), and ejaculatory disorder (1.2%) compared with 1.3%, 0.7%, and 0.7% on placebo, respectively [4]. The absolute difference is small. For transgender women, the clinical relevance of these categories differs substantially: erectile function and ejaculatory status are not primary endpoints for most transgender women using feminizing therapy, and libido changes may be attributed to estradiol as readily as finasteride.

Mood effects have been reported anecdotally, including depressive symptoms and cognitive complaints. A pharmacovigilance analysis of the FDA Adverse Event Reporting System found that depression reports were disproportionately associated with finasteride compared with control drugs, though reporting bias and causality remain unresolved [11].

Post-Finasteride Syndrome

Post-finasteride syndrome (PFS) refers to a cluster of persistent sexual, neurological, and psychological symptoms reported after discontinuing finasteride in cisgender men. The FDA added a label update in 2012 noting that sexual side effects may persist after discontinuation. The mechanistic basis is debated; proposed explanations include neurosteroid pathway disruption and epigenetic changes in androgen receptor expression.

The Post-Finasteride Foundation has published case series, but no prospective cohort with a concurrent control arm has quantified the incidence of persistent symptoms in a way that satisfies epidemiologic standards. A 2020 systematic review in JAMA Dermatology acknowledged PFS as a clinically recognized phenomenon while noting the incidence estimate of 1 to 2% in cisgender men was based on low-quality evidence [12].

For transgender women, no published data specifically describe PFS incidence or phenotype. Given that ongoing feminizing therapy alters the baseline hormonal milieu substantially, any extrapolation from cisgender male data requires caution.

Cardiovascular and Oncologic Considerations

The PCPT trial (N=18,882) found that finasteride reduced prostate cancer incidence by 24.8% overall but was associated with a higher proportion of high-grade (Gleason 7 to 10) tumors among cases diagnosed in the treatment arm [13]. The FDA updated labeling accordingly in 2011. In transgender women with a retained prostate who have been on long-term estrogen therapy, prostate cancer risk is already reduced, but it is not zero. Clinicians should document retained prostate status and maintain appropriate screening discussions even on finasteride therapy.

Cardiovascular data from cisgender male trials do not show a direct cardiac risk signal for finasteride at approved doses. The PLESS trial 4-year safety data reported no excess cardiovascular events [3].

Laboratory Monitoring Protocols

Baseline Labs Before Starting

Clinicians should obtain serum total testosterone, DHT, LH, FSH, estradiol, complete metabolic panel, and a complete blood count before initiating finasteride. Liver function testing is standard because finasteride is metabolized by CYP3A4 and rare hepatotoxicity has been reported in postmarketing surveillance.

PSA (prostate-specific antigen) should be measured at baseline if the prostate is retained, because finasteride typically reduces PSA by approximately 50% within 6 months. A PSA that does not fall on finasteride, or that rises from a post-treatment nadir, should prompt urologic evaluation regardless of absolute value.

Follow-Up Schedule

The following schedule reflects current practice at gender-affirming care centers and the Endocrine Society monitoring recommendations:

• 3 months: Serum DHT, total testosterone, estradiol, LH, FSH, potassium (if on concurrent spironolactone), and PSA (if prostate retained)
• 6 months: Same panel plus liver function tests
• 12 months: Same panel; reassess therapeutic goals and patient-reported outcomes
• Annually thereafter if labs are stable and patient is tolerating therapy

DHT target is generally below 20 ng/dL on therapy, though no guideline has formally defined a gender-affirming DHT target. Some clinicians aim for below 15 ng/dL when scalp hair preservation is the primary indication.

Patient Selection: Who Is Most Likely to Benefit?

Finasteride is not appropriate for every transgender woman or nonbinary AMAB patient. The clearest candidates are those who:

1. Have testosterone suppressed below 50 ng/dL on current estradiol therapy but retain DHT-driven scalp hair loss (androgenetic alopecia pattern)
2. Cannot tolerate spironolactone due to hyperkalemia, renal insufficiency, or intractable urinary frequency
3. Are using bicalutamide and want additional DHT blockade specifically for scalp and skin endpoints
4. Are post-orchiectomy with gonadectomy, where total testosterone is very low but DHT from adrenal precursors may still be measurable

Patients who have not yet started feminizing therapy and whose primary goal is broad androgen suppression are better served by spironolactone, bicalutamide, or a GnRH agonist as the primary antiandrogen. Finasteride alone does not suppress testosterone adequately to drive feminizing changes.

A history of depression or mood disorder warrants explicit discussion of the mood-related adverse event signals before prescribing, given the unresolved PFS data.

Shared Decision-Making and Informed Consent

The American Society of Reproductive Medicine, the Endocrine Society, and WPATH all support an informed consent model for gender-affirming hormone therapy. For finasteride specifically, the informed consent discussion should cover:

• The off-label status and the absence of RCT data in transgender populations
• The distinction between DHT reduction and testosterone suppression
• Sexual side effect rates from cisgender male data (approximately 3 to 8% any sexual complaint in trials)
• The PFS signal and the scientific uncertainty about its incidence and persistence
• Alternative antiandrogens and their respective risk profiles
• The expectation timeline: DHT falls within days of initiating finasteride, but hair and skin changes require 6 to 12 months to become clinically apparent

Documentation of this conversation in the medical record is both ethically appropriate and medicolegally protective for the prescribing clinician.

Fertility Considerations

Finasteride is classified FDA Pregnancy Category X (teratogenic in animal models). For transgender men, nonbinary AFAB patients, or cisgender women, inadvertent exposure is a concern. For transgender women or nonbinary AMAB patients who have not undergone orchiectomy and may wish to preserve fertility, finasteride does not directly impair sperm production the way GnRH agonists do, but the context of concurrent estradiol therapy already reduces spermatogenesis substantially. Sperm banking before initiating any feminizing hormone therapy is the standard recommendation per the Endocrine Society 2017 guideline [2].

Pregnant individuals or those planning pregnancy should not handle crushed or broken finasteride tablets because dermal absorption of DHT inhibitors carries risk of external genitalia development abnormalities in a male fetus, as documented in product labeling [10].